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edawar's characterization 
of rejection I as a host-
versus-graft (HVG) reac-
tion (Fig. 1 a) was the cor-
Recen/ "(lidence slisgests tl1l1l 
pllSSel1ger lellkocytes migrate lifter 
orglll1 ImllSpl11l1tlltiol1 IIl1d prodltCI' 
persis/I'lll chimerism, which is 
I!:"senlia/ for su5lained slIruil'l1/ of 
tlte lI11ogmfls . Hcre, TllOll1l1S 5111r::.1 
donor and recipient immune-cell popu-
lations coexisted in neonatally tolerant ani-
mals in a mutually nonreactive state while 
retaining the ability to function colla bora-
tively (e.g. in a joint immune response to in-
fection) was abandoned when no direct ex-
perimental support could be found lO . 
However, it has since been learned that the 
outcome in the neonatal tolerance model is 
highly variable and that a state approaching 
permanent clonal deletion is uncommon". 
Recently, it has been shown that the ability 
nerstone of transplantation immunology. A 
decade later, this concept was transposed 
in the context of a graft-versus-host (GVH) 
reaction (Fig. 1b), in which histoincompat-
ible hematolymphopoietic grafts rejected 
the immunologically defenseless recipients2•3 
The resulting assumption that allograft 
and col/engllcs argile thl1l Ihls 
i1eIllI110!Y',lplwpaiet if chil1lcr/SIII 
prmlidcs nil imporlnHI framework 
for tlze interpretntioll of bnsic nnd 
tilempelltim/ly orienled 
tmnsplnntntiol/ researcil. 
acceptance or rejection could be understood 
by studying HVG or GVH immunologic responses in isolation led of donor-derived leukocyte subsets to proliferate in response to a 
to prompt acceptance of the one-way in vitro tests of immune reac- skin graft challenge was a more critical determinant of neonatal to 1-
tivity as 'minitransplant' surrogates. However, this assumption did erance outcome than the baseline level of chimerism12 , 
not provide a blanket explanation for observations made in animal 
and human allograft recipients, 
The one-way paradigm 
Until 1959, preparatory donor leukocyte infusion into cytoablated 
organ recipients was an expected natural extension of the neonatal 
tolerance model of Billingham, Brent and Medawarl and its adult 
cytoablation analogues5 , However, when long-term survival of 
human kidney allografts was accomplished in a few sublethally 
irradiated recipients without donor leukocyte infusion, and then 
regularly without cytoreduction under continuous pharmacologic 
immunosuppression, the need either for chimerism or host 
preconditioning lost favor, 
The identification of 'passenger leukocytes' as the primary anti-
genic component of organs6.7 led to the belief that their destruction 
by the host immune system was essential for organ engrafhnent. 
When these cells were found to be migratory, including dendritic 
cells (DCs)9, their sensitization effects and presumed elimination at 
peripheral and intragraft sites was taken for granted. 
Bone marrow transplantation 
Major histocompatibility complex (MHCl-restricted models of ac-
quired tolerance were widely considered to have validated Burnet's 
prediction that developing lymphocytes could be purged of self-
reactive cells before they achieved functional maturity, even follow-
ing bone marrow transplantation, The alternative pOSSibility that 
Orgon transplantation 
The conclusion that organ transplant acceptance was by different 
unidirectional mechanisms than those of bone marrow grafts was 
reinforced by the striking differences between the two varieties of 
procedures (Table 1). In addition, it was generally assumed that 
cytoablation (or cytoreduction) to 'make microenvironmental 
space' was a necessary condition for leukocyte engraftment and 
chimerism, in spite of early and recent evidence to the contrary 
(reviewed in Ref. 13) , 
The two-way paradigm 
A link between bone marrow and organ transplantation was pro-
vided when microchimerism was detected with sensitive immuno-
cytochemical and polymerase chain reaction (PCR) techniques in 
the tissues or blood of all 30 human kidney or liver recipients stud-
ied from 2.5-30 years postoperatively14·IS (Fig. 1c) . Many of the 
donor cells appeared to be DCs, potent antigen-presenting cells 
(APCS)' 6. Individual samples often do not contain the donor leuko-
cytes, which wax and wane'7. However, disseminated donor cells, 
including DCs, and/or donor DNA are consistently found if 
rodents bearing long-term grafts are thoroughly studied
'
6-20. 
Along with peripheral migration of the donor cells from a suc-
cessfully transplanted graft, there is an influx of host leukocytes 
that do not cause graft damage (Fig. 1C)'S: both the allograft and re-
cipient become genetic composites. A mirror image condition exists 
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Fig. I. (Upper palIels) One-way paradigll1 in which trnllsplmJtatiolJ is collceived as involving a LlIJidirecfional imm~/f1e reaction: (a) host-versus-grnft 
(HVG) with whole organs and (b) grnft-versuS-host (GVH) with bO/Je marrow or other lymphopoietic transplalJts. (Lower panels) Two-way paradigm in 
which tmIJsplantation is seen as a bidirectiollal alld IIIlItually cancelling imll11111e reaction that is (c) predominantly HVG with whole orgall grafts, and 
(d) predomillallt ly GVH with bone lIIarrow gmfts. 
after bone marrow transplantation11 (Fig. 1d), proved by demon- In a reassessment based on the discovery of microchimerism in 
strating a trace residual population of host leukocytes in essentially organ recipients, we suggested that the donor leukocytes in organ 
all stable, human bone marrow recipients who previously were recipients were co mponents of antagonistic but reciprocally ilttenu-
thought to have complete donor-cell chimerism"- ated or abrogated HVG and GVH armsI4.,S.1,. Deletion of the host 
Cause or effect? 
In the one-way paradigm, which excludes a role for lymphoid cell 
microchimerism, it has become axiomiltic that antigens of the 
parenchymal (or vascular endothelial) cells of trilnsplanted organs 
permit or induce allograft acceptilncel.1 in various ways, e.g. via 
veto /suppressor cells, cytokine profile changes or enhancing anti-
bodies. Furthermore, it has been argued that the microchimerism 
associated with successful transplantation, and conversely its dis-
appearance with or just after irreversible rejection in experimental 
models 1B.20, is epiphenomenal"-
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arm by cytoablation prior to bone marrow but not organ trans-
plantation altered the balance in this mutual antagonism and was 
thus responsible for the disparities in the two different kinds of 
transplantation (Table 1) . 
The microchimerism had consequences that could not be ex-
plained by the simple presence of antigen, as long as the balance 
was not disturbed and both cell populations were equally immuno-
suppressed. The dynamic 'nullification' effect of the two arms 
explained (1) the poor prognostic value of HLA matching for organ 
transplantation; (2) the rarity of GVH disease (GVHD) following 
the engra ftment of immunologically active organs, such as the 
intestine and liver14·,5.1" and (3) the characteristic cycle of irrununologic 
Table I. Differences between conventional bone 
marrow and organ transplantation 
Bone Marrow Feature Organ 
Yes Recipient cytoablationa No 
Critical MHC compatibility Not critical 
GVHD Principal complication Rejection 
Common Drug free state Rare 
Tolerance Term for success 'Acceptance'b 
Abbreviations: GVHD, graft-venK~hMRt disease; MHC, major histocompa t-
ibihty complex, 
"All differences derive from this therapeutic step which in effect establishes 
an unopposed eVH reOlction in the bone marrow recipient whose counter-
vailing immune reaction is eliminated 
I>()r 'operational tolerance', 
Immune 
reaction 
§munosuppression 
Time after transplantation 
Fig, 2, Simultaneous Itost-versus-graft (HVG) and gmft-versus-host 
(GVH) reactions in tlte two-way paradigm of transplantation immllnology 
Fol/owillg the initial interaction, the evolution of nonreactivity of 
eaclt leukocyte population to the other is seen as a predominalllly low-
grade stimulaton) state that may wax and walle, ratlter titan a deletiolwl 
one. 
crisis and resolution, first observed in kidney recipients25, that was 
most-practically monitored by serial changes in organ allograft 
function (Fig. 2). 
Finally, the discovery of chimerism cast new light on the 
B-cell lymphomas [post-transplant lymphoproliferative disorders 
(PTLDs»), that are usually of host origin in organ recipients and 
of donor origin after bone marrow transplantation. Except for 
their frequent Epstein-Barr virus association, these human malig-
nancies are indistinguishable from those induced by Schwartz in 
a mouse chimerism model26 three years before the PTI..D complica-
tion was first recognized clinically27 and explained by simple loss of 
surveillance28. By contrast, Schwartz ascribed the tumors to a ly,m-
phoproliferative response by the dominant immune apparatus to 
the persistent subclinical GVH counter-attack of the minority leuko-
cyte population. The relevance of this conclUSion, of 'Schwartz's 
rules' of pathogenesis, and of their therapeutic implications could 
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not be appreciated until three decades later in the context of the 
two-way paradigm29 . 
The role of immunosuppression 
As in Schwartz's 'lymphoma-genic' experiments, immunosuppres-
sion is a temporary requirement for reliable induction of tolerance 
in numerous rodent organ allograft models. The same is true, but 
unpredictably, after liver30 and, less commonly, kidney transplan-
tation in outbred canines. Moreover, successful liver transplantation 
induces tolerance with no treatment at all in a significant percent-
age of outbred pigs as well as several ratlO,31 and virtually all mouse 
strain combinations
'
"' Mouse heart and kidney allografts are also 
accepted spontaneously in a much more limited number of MHC 
disparate conditions (reviewed in Ref. 19). When a thorough search 
is made for microchimerism in the rodent models, it can always be 
found 19.20.32, 
In all these species, the organs pass through an acute self-
resolving rejection on the way to tolerance, which usually extends 
to subsequent transplantation of other donor-strain tissues and 
organs33 The tolerance is stable despite evidence from in vitro test-
ing that anti-donor reactivity is retained (split tolerance)'9.20,31,34 or 
can be restored by the addition of appropriate cytokines. 
The cumulative weight of the above observations does not sup-
port the possibility that microchimerism is a passive consequence 
of organ transplantation. Instead, an active role of the organ-
associated chimerism can be identified in a continuum of classical 
tolerance models beginning with the original observations by 
Owen in Freemartin cattle (Fig. 3). 
Th e stem cell question 
The human chimerism studies suggested that hematopoietic stem 
and precursor cells were among the migratory cells from trans-
planted organs. In support of this contention, all lineages in supra-
lethally irradiated mice can be reconstituted efficientl y by the infu-
sion of non-parenchymal cells with stem cell phenotype, isolated 
from syngeneic adult mouse livers3s In addition, irradiated rats can 
be reliably reconstituted with orthotopic liver transplantation 
ra ther than bone marrow36 
Importantly, heterotopic heart transplantation also results in per-
manent hematopoietic reconstitution in occasional irradiated rats36, 
a rescue that is increased to ;;.70% by the post-cardiac transplant ad-
ministration of lisofylline (N. Murase et aI. , unpublished) . Liso-
fylline is a phosphatidic acid inhibitor that facilitates bone marrow 
engraftment by suppressing hematopoiesis-inhibiting cytokines 
(e.g. tumor necrosis factor ex, transforming growth factor 13, macro-
phage inhibitory protein lex and platelet factor 4) that are typically 
released in response to activation stimuli in the post-transplant 
period, while not altering levels or activities of the myeloid, 
progenitor-cell-promoting cytokines, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and G-CSF (Ref. 37). 
Such experiments show that the chimerism produced with 
bone marrow infusion vs. conventional organ transplantation is 
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the same, with apparent differences that 
are largely determined by the radically diver-
gent treatment regimens. Consistent with 
this, the chimerism following transplanta-
tion of the bone-marrow-containing hind limb 
to non-cytoablated recipients is much the 
same as after engraftment of parenchymal 
organs3S . 
Freemartin cattle (1945) Parabiosis (1960) Organ 
transplantation 
(1992) 
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However, in practical terms the outcome 
(HYG, GYHD or both) is strongly influ-
enced by the lineage profile of the mature 
immunocytes contained either in different 
vital organs (hea rt, kidney, liver and intes-
tine) or in cell suspensions prepared from 
various primary or secondary lymphoid or-
gans. Non-parenchymal cells of the liver (the 
most tolerogenic whole organ) resemble 
those of bone marrow (the lymphoid organ 
yielding the most tolerogenic cell suspen-
sion). Both includ e higher numbers of im-
mature leukocytes and cells of myeloid origin 
than the lymphocyte-rich and GYHD-prone 
intestinal allograft and lymph node or spleen 
cell suspensions2o 
Fig. 3. The contillllulIJ of chimerislIJ from observntioJ15 of R. Owen ill Freemnrtin cntt/e, wiJich wns 
rejected ns n meciwnistic explnnntion of orgmJ allogrnft ncceptnl1ce frollJ J 960 until the discoverlj in 
J 992 of IIlicrochimerislll in orgnn recipients. 
Chimerism: level and duration 
The implication of human and animal studies is that the threshold 
level of circulating donor leukocytes necessary for a tolerogenic ef-
fect has been set too high. Although treatment strategies that di-
rectly18.19 or indirectly augment chimerism37•39 in non-cytoablated 
experimental animals increase the reliability and comple teness of 
tolerance, it is not at all clear that the process can be fundamentally 
hastened . One postulate is that the chimeric immune cells remain 
susceptible to further signals that reinforce specific nonreactivity in 
stages40 Rather than accelerating these steps, we have suggested 
that immunosuppressive agents, with diverse sites of action, merely 
permit them to develop (with variable success) by allowing the 
same underlying function of the immune system to be expressed as 
in models of spontaneous tolerance41 (see earlier). 
With liver transplantation in spontaneously tolerant and 
'immunosuppression-assis ted' rodent models, the cause (chimerism) 
and effect (tolerance) are induced almost simultaneously but these 
related events are usually separated by months or yea rs in outbred 
animals and humans (Fig. 4) . Many long-surviving human liver re-
cipients have become immunosuppression-independent (most fre-
quently because of treatment noncompliance) at highly variable 
postoperative times (Fig. 5). More-complete information was ob-
tained in a prospective weaning trial of liver recipients who had at 
least five years of stable allograft function 42 The majority of these 
• No immunosuppression 
Mouse ? 
Immunosuppression needed 
, Outbred 
Rat 
? 
Pig' 
? 
Dog' 
? 
Human' 
, 
, 
?, 
, 
Week Month Year , Decade , ? 
Fig. 4. Time between cause Ichimerism} and cffect IdOllor specific toler-
ance} nfter liver nllotrnnsplantation in different species . Note thnt imJllJlJlO-
suppression is not IJIliversnlllj required ill three of the five species showll . 
The desired drug-free state might never be reached in a propor-
tion of human liver recipients, but the disseminated donor-derived 
leukocytes (and their companion organ) apparently can be main-
tained for a lifetime under immunosuppression . The same principle 
has been demonstrated in rat cardiac and renal recipien ts in which 
continued immunosuppression prevented the slow disappearance 
of chimerism and the onset of indolent chronic rejection2o 
As in animals, discontinuance of drug therapy in humans is 
patients were able to stop immunosuppression or are still in an un- thought to be more dangerous after transplantation of organs other 
interrupted weaning process·3: 30% developed rejection, necessitat- than the liver. However, five of the ten longest-surviving patients 
ing resumption of immunosuppression. No grafts were lost or had bearing Ji ving-related kidney allografts have been completely off 
permanent impairment of function. immunosuppression for between three and 30 years (Table 2). 
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Fig. S. Time on (green) and off immunosuppression (ornnge) of 12 (28%) 
of our 42 longest-surviving liver recipients (15-26 years posl-lrnllspll1nl) 
WilD are receiving no trealmenl as of December 1995. These drllg-free 
patients remain well in September 1996. 
Patients 3 and 4, whose mixed lymphocyte response (MLR) tests to 
donor and third party targets were profoundly depressed prior to 
weaning", had gradual restoration of MLR to both in the drug-free 
state, but with no evidence of rejection. 
There is no empirical method to determine the necessary du-
ration of continued immunosuppression for maintenance of stable 
chimerism and allograft function in humans. Thus, quantitation of 
donor-derived leukocytes cannot be used to plan drug weaning 
protocols for patients . This must be done by cautious trial, with 
precautions to prevent irreversible error. 
Genetic (actors 
Although the genetic basis for immune reactions is beyond ques-
tion, the MHC effect is unambiguously evident only when the re-
cipient is immunologically defenseless: i.e. in the neonatal tolerance 
model, recipient cytoablation in all species, or as the consequence of 
breeding (e.g. the F, hybrid preparations). When the recipient im-
mune system is competent, organ transplantation outcomes have 
defied detailed genetic analyses, even in con genic mouse'9 and rat 
models·s.' 6 A clear prognostic effect of MHC after organ transplan-
tation in immunologically intact humans has been clearly identifi-
able only with a perfect or near perfect HLA match'? The lack 
of predictability can be explained by the interaction implicit with 
chimerism in which each population follows its own genetic 
program. 
MHC did not evolve for immunologic segregation of transplant 
patients and their tissues but rather to meet the need of popu-
lations, not individuals, for immunologic flexibility: allograft rejec-
tion was an unforeseen byproduct of modern technology. Trans-
plantation of surgically revascularized allografts was, in essence, no 
different than the induction and then the control of an organ-
specific autoimmune disease. Thus, there were no hard genetic 
rules that prohibited chimerism or successful organ transplantation. 
Cellular and molecular mechanisms 
So-called 'parking' experiments, in which grafts are temporarily 
placed in a third-party recipient prior to retransplant into the 
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intended host, have been put to good use in transplantation re-
search7 •• B';". However, we would argue that the presence of altered 
(nonreactive) leukocytes that repopulate an organ during reSidency 
in the intermediary allogeneic host make such retransplantation 
models inappropriate for the study of complex tolerance mecha-
nisms. In addition, the leukocyte replacement during the parking 
period is incomplete. Even at one year of residence in a tolerant re-
cipient, 10% of the non-parenchymal cells remain donor, a propor-
tion that is essentially fixed from day 100 onward'B Not surprisingly, 
the results following retransplantation are hard to interpret-"l,; , . 
In simpler experiments involving only the depletion of organ 
leukocytes by donor irradiation or other means, both the tolero-
genicity and antigenicity of hear~19I livers2 and free pancreas islet 
allografts51 are abrogated or weakened, The tolerogenicity of liver can 
be restored by an infusion of donor-strain splenocytes into irradiated 
donors 24 hours before the organ is removed for transplantation'i-l. 
The same is true of islets after adding back donor leukocytes. 
In contrast to the interpretive artefacts introduced with 
the parking models, successful transplantation in the two-way 
paradigm is defined as persistent chimerism, whether or not it is 
immunosuppression-dependent. A failed transplantation connotes 
the therapeutically uncontrollable ascendency either of HVG or GVH 
(Refs 15, 41). Pathologic evidence of both processes is frequently 
found in failed cases, but the ultimate result is predominantly 
rejection or GVHD. 
In this context, the vast literarure addressing the basis of toler-
ance, and that preoccupied with rejection, can be brought to bear on 
problems of transplantation. Many experiments have been one-way 
paradigmatic, showing the effects of exogenous or transgenic anti-
gen on T cells and other immune cell subpopulations. The interpre-
tation of such data in transplantation must encompass the al-
terations in two cell populations, each of which can modulate the 
other. In addition to a murual antigen stimulus, the two-way para-
digm implies active protection of the coexisting arms (GVH or 
HVG), which is particularly important if one cell population is out-
numbered or if there is severe MHC disparity. Such a reciprocal 
'defensive' mechanism of graft enhancement has been the subject 
of investigation but only in connection with hematolymphopoietic 
reconstitution after recipient cytoablation55-57 
Experimental manipulations under highly controlled conditions 
are usually directed at understanding T-cell tolerance, However, T 
cells are only one of a number of specialized immune regulatory 
leukocytes. For instance, Burlingham el al. 58 have isolated a circu-
lating donor leukocyte, resembling the veto cell of Miller'", in a tol-
erant human kidney recipient with such powerful function that a 
single cell could neutralize the ill vitro activity of ]0 000 reCipient 
CTLs. 
The possibility that transplantation tolerance is governed by 
APCs was raised by the invariably prominent presence of DCs in 
chimeric human",! ; and animal organ recipients 's,,". Using culture 
techniques adapted from lnaba el al."', donor-derived DC precur-
sors have been propagated from d isseminated locations in mouse 
reCipients of spontaneously accepted liver allografts6L these are 
co-localized with recipient DCs that are undergoing the same 
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changes6,.62 These immature DCs, which are 
phagocytic63 and deficient in surface costim-
ulatory molecule expression (B7 family)64, 
have been shown to induce T-cell anergy 
in vit ro64 and to prolong organ allograft 
survival65 
Table 2. Discontinuance of immunosuppression in long-term living 
related kidney recipients3 
Years post- Haplotype Indication for 
Patient transplantation mismatch weaningi' Years off drugs 
33 0 nc 30 
2C 32 comp IS 
3 32 0 nc 29 
4c 32 2 comp 0.5-3 
SC 33 comp 3 
Such dues are intriguing, but it is 
unlikely that allograft acceptance can be 
fully understood from the results of studies 
of individual leukocyte lineages. Overall, 
the mechanisms of transplantation tolerance 
suggests learning adaptive immune func-
tions of the whole system involved in self-
integrity (i.e. cytokines, immunoregulatory 
cells, antibodies and other factors) . 
These ~re 3 of the 161ongest-tunctioning allografts in the world. 
"comp, complic.,tions: skin cancer, warts, iniection, hypertension, obesity and orthopedic problems. 
nc, non-compliant. 
'These were children <1t the time oi transpl.lntation. 
Transplant tolerance: central or 
peripheral 
The role of the thymic vs. peripheral mechanisms in graft accept-
ance under both experimental and clinical circumstances has been 
controversial60-68. The prompt appearance of donor-derived leuko-
cytes in the recipient thymus following organ transplantation'6 was 
of particular interest because of the strikingly tolerogenic effect in 
rodents of intrathymic inoculation of donor leukocytes53 However, 
thymectomy in adult rats does not inAuence either the chimerism or 
spontaneous tolerance induced by liver transplantation69 
Dejbakhsh-Jones e/ 17/.'0 have shown that, after thymectomy and 
lethal irradiation, adult mice reconstituted with purified hemato-
lymphopoietic stem cells developed similar levels of a~ T cells to 
those seen in control animals except for a reduced proportion in the 
spleen. 
Between 1962 and 1965, 32 patients, including 24 who were part 
of a controlled randomized trial, underwent transthoracic thymec-
tomy from 8 to 112 days (average 22) before renal transplantation 
either from living related or unrelated donors. Between 3.5 and 7 
years later, no clinical differences were apparent between the 
thymectomized and control recipients, although there was a trend 
towards better histopathology in the thymectomized group71 . In 
1992, comprehensive in vitro immunologic studies of many of the 
remaining recipients and their donors did not reveal any distin-
guishing features of one cohort vs. the other (G. Shearer and 
A. Zeevi, unpublished). After 25 to 30 years, the thymectomized 
patients had no clinical advantage or disadvantage. 
Therapeutic implications 
In the context of the two-way paradigm, early efforts to improve 
transplantation results with donor-specific blood transfusionn and 
the donor bone marrow augmentation of organ recipients?3.,. were 
based on sound therapeutic principles involving the unrecognized 
augmentation of chimerism. Also in retrospect, it is obvious why 
whole organs are inherently tolerogenic as first convincingly 
demonstrated by Caine e/ a/ .32 
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Understanding the concept of a donor-recipient leukocyte dia-
logue should help predetermine what can (and cannot) be accom-
plished with various tOlerance-inducing strategies, all of which are 
attempts to inAuence this interaction. Our first clinical premise 
was that the spontaneous microchimerism of organ transplantation 
could be greatly augmented by the co-administration of unmodi-
fied donor bone marrow cells without a significant risk of GVHD, 
providing the two immunocyte populations were initially compe-
tent and that immunosuppression was delivered to both equally. It 
was also predicted that the timing, severity and frequency of acute 
rejection would be approximately the same as in non-bone-marrow-
augmented control patients"·"·75. 
These expectation's have been fulfilled in 150 human organ re-
cipients treated at the Un iversity of Pittsburgh 75.76 The presence of 
donor DNA in the myeloid and erythroid colonies generated from 
recipient'S peripheral blood mononuclear cells (PBMCs) as meas-
ured in standard?6 or innovative clonal hematopoietic progenitor 
cell assays77 has provided unequivocal evidence of augmented stem 
cell chimerism. There were no examples of significant GVHD. 
The hypotheses of therapeutic efficacy being tested were that the 
threat of delayed (acute or chronic) rejection could be reduced and 
that the frequency of ultimate drug independence would be in-
creased by the higher persistent level of chimerism. An efficacy 
evaluation is expected to take 5-10 years·', roughly the same time 
frame mapped out by clinical experience with MHC-incompatible 
liver and bone marrow transplantation (Figs 4 and 5). 
Other chimerism-enhancing strategies (e.g. G-CSF, GM-CSF or 
lisofylline) should follow the same safety l efficacy rules. By con-
trast, procedures that alter only one of the interacting arms must be 
approached with caution, as exemplified by the historical experi-
ence with GVHD following cytoablation and bone marrow trans-
plantation. When the converse tactic of leukocyte or T-cell-specific 
depletion of intestinal allografts was attempted as GVHD-
prophylaxis in the 1980s, virtually every bowel recipient who sur-
vived the perioperative period developed lethal Epstein-Barr-virus-
associated B-celllymphomas 711 • 
In an experimental example of unbalance which has potential 
clinical relevance, prior induction of tolerance with bone marrow 
in briefly immunosuppressed rats followed by delayed liver 
transplantation resulted in GVHD (Ref. 19), a complication not seen 
after either bone marrow or liver transplantation, or both simulta-
neously. The results of the second stage transplantation resembled 
those in the parent to defenseless offspring F, models. 
Conclusion 
The assumption that stem cell driven hematolymphopoietic 
chimerism was irrelevant to successful whole organ transplan-
tation, as currently practiced, has led to inadequate explanations of 
organ allograft acceptance and clouded the meaning of successful 
bone marrow transplantation, thus precluding the development 
of a central priI1cipie of transplantation. Incorporation of the 
chimerism factor into a two-way paradigm has allowed previous 
enigmas of organ and bone marrow engraftment to be explained 
and should allow key advances in basic immunology to be more 
meaningfully exploited in transplantation 
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Chimerism and transplantation tolerance: 
cause and effect 
Kathryn Wood and David H. Sachs 
I!"- .... - ... onor cells or genet ic ma-
terial can often be detected 
in recipients following trans-
• __ ..... plan tation of a solid-organ 
allograft. Such recipients are described as 
exhibiting peripheral donor microchimerism 
and in some cases the donor material is de-
tected for long periods after trans plan-
tation'-S It has been suggested not only that 
peripheral donor microchimerism is associ-
ated with long-term acceptance of the organ 
graft but that it plays an active role in the in-
duction and maintenance of unresponsive-
Ei'idel/ce for persistence of dOllol' 
leukocytes il/ reripiellts of 10llg-tmn 
Ol'gall allograftslras plOl1Ipted 
the hypothesis that -I/ch 
lIIic/'ochiIJ/C!l'islll IS lIot 01//1/ 
esst!IItialto gra f SI/I'l,'wa! bIll that 
dOllol' alld 1I0st cell.; both play 
active roles. Here Knfhryll Wood 
IIlld David Saclls fnlltlOll thai Ihe 
jllry is still 0111 011 whC!t/wr :lIch 
microchilnl!l'IslIl is the calise 01 
merely thl! COlIst'qllellct' of IOllg-term 
allogmftlllg_ 
Microchimerism: observations 
Solid-organ grafts contain passenger leuko-
cy tes7,8, the number and lineage of which 
vary conSiderably among d ifferent organs. 
For example, the liver contains an abundant 
supply of passenger cells, whereas rela-
tively few leukocytes are present within the 
heart9 In addition, the passenger leukocytes 
present in the liver of rodents contain a suf-
ficient number of haematopoietic stem 
cells'o to rescue a lethally irradiated recipi-
ent when a syngeneic liver graft is trans-
ness'-J·6. This hypo thesis, first proposed by Starzl and colleagues in 
1992 (Ref. 1), has stimula ted a great deal of interest and actiVity in 
the transplant community. However, from the published reports to 
da te, it remains difficul t to determine whether such micro-
chimerism is the cause or the consequence of long-term graft 
survival. 
planted; rescue cannot be achieved reliably 
by the transplantation of a syngeneic cardiac allograft" . Passenger 
leukocytes present within solid organs have been isolated and 
shown to possess the potential to stimulate immune responses in 
vitro12. However, before acquiring full immunostimulatory poten-
tial, it appears that such cells must develop into a more mature 
form. This has been achieved in vilro by addition of growth factors , 
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such as granulocyte-macrophage colony-
stimulating factor (GM-CSF) and a period of 
culture '2.1J. On the basis of these observa-
tions it has been suggested that some 
passenger leukocytes are immature den-
dritic cells 1 •. {II vivo, passenger leukocytes 
present within an organ graft have been 
shown to migrate from the graft to recipient 
lymphoid tissue after tr~nsplantationDRK DS: 
donor derived, major histocompatibility 
complex (MHC) class U- leukocytes could 
be detected in the spleen within 48 hours 
of transplantation of a heart allogr~ft into 
a naive mouse' 6, Within the spleen, the 
donor leukocytes were associated with 
CD4" T cells and it was suggested that 
this interaction is responsible for initiating 
the rejection response in non-immuno-
suppressed recipients 1". These data support 
the conclusion drawn in earlier studies by 
Lechler and Batchelor that intragraft passen-
ger leukocytes, most probably dendritic 
cells, provide the major stimulus for graft 
immunogenicity", 
In support of this hypothesis, organs de-
pleted of passenger leukocytes have been re-
ported in some cases to enjoy prolonged sur-
vival without administration of exogenous 
immunosuppressive therapy 17-21. [n some of 
these studies, organs were depleted of pas-
senger cells by 'parking' the graft in a pri-
mary recipient receiving immunosuppres-
sive therapy' 7.1Q.20 Such ' pilrked ' organs 
from long-term surviving primary recipi-
ents were then re-transplanted to fresh non-
immunosuppressed syngeneic secondary 
recipients and the survival of the graft moni-
tored . In some strain combinations, the 
passenger-cell-depleted kidneys survived 
indefinitely and in others they showed 
prolonged survival. Interestingly, in these 
studies, induction of chimerism by the ad-
ministration of donor bone marrow to the 
secondary host before transplantation led to 
graft rejection, as did the administration of 
dendritic-cell-enriched leukocytes". 
In primary graft recipients, donor leuko-
cytes migrating from transplanted hearts in 
a mouse model were only detectilble for a 
few days within the spleen unless the ani-
mals received immunosuppression, after 
Fig. 1. A compnrison of tlte n;icroc/limeriSIII detected fo/lowillg n/log~lleic orgoll trnllsplnlltntioll which donor cells could be detected for 
lISillS stolldnrd imm1ll10Sllppressioll, ond tlte chimerism estnblished by illtelltionnl bone morrow longer periods following tranSplantation. In 
trflllsplnlltntion prior to 011 orgflll trnllsplnllt . some human kidney transplant patients, 
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donor material has been detected in the periphery more than 25 
years after transplantation3. Impressively, donor-derived cells have 
been detected in some patients with stable graft function who have 
stopped taking immunosuppressive drugs22. However, the detec-
tion of donor-derived material or cells in patients with long-term 
surviving organ grafts is not a consistent finding . For example, in a 
study carried out in Paris, donor microchimerism could only be de-
tected in a third of patients who had exhibited long-term stable kid-
ney graft function for more than 20 years" Therefore, the role that 
donor leukocytes migrating from an organ graft to the peripheral 
tissues of the recipient play in either the induction or maintenance 
of unresponsiveness to the organ graft is unclear. No correlation be-
tween the state of microchimerism and the absence of acute or 
chronic rejection was found in heart transplant patients'. Moreover, 
donor-derived material was detected in a patient undergoing graft 
rejection eight years after liver transplantationH If extended donor 
microchimerism plays a role in the development of unresponsive-
ness to the graft, it is surprising that it can be detected in this 
situation. 
In contrast to donor microchimerism detectable after organ 
transplantation, haematolymphopoietic chimerism is achieved at 
readily detectable levels following administration of allogeneiC 
bone marrow to appropriately conditioned recipients. In this situ-
ation, bone marrow engraftment generally requires the dual strat-
egy of ablation of the host's haematopoietic system, in order to 
'make room' for the donor marrow, along with additional immuno-
suppression to prevent rejection of the allogeneic cells: the former is 
usually achieved by irradiation or radiomimetic drugs, the latter by 
T-cell depletion or by immunosuppressive agents. 
When bone marrow transplantation is performed to treat haem-
atologic malignancies, complete ablation (e.g. lethal irradiation) is 
immunosuppression, and the chimerism established by intentional 
bone marrow transplantation prior to an organ transplant (Fig. 1). 
In the former case, the chronic immunosuppressive regimen must 
be sufficient to suppress rejection of the graft. and as such it is un-
doubtedly also sufficient to suppress the elimination of donor cells 
which might escape from the transplanted organ. Therefore, detec-
tion of such cells elsewhere in the recipient might be considered as 
evidence of microch imerism, but it does not imply that the cells 
detected are the ca use of the graft's acceptance. On the contrary, they 
may be the result of the graft's acceptance and of the immuno-
suppression required to maintain that acceptance. 
By contrast, when chimerism is established by deliberate bone 
marrow infusion following T-cell depletion of the recipient, and par-
tial or complete ablation of the recipient's lymphohaematopoietic 
system, this chimerism is clearly the cause of tolerance2s27-29 In this 
case, subsequent transplants of other tissues or organs from the same 
donor are uniformly accepted without the requirement for additional 
long-term immunosuppression. Moreover, the loss of tolerance fol-
lowing elimination of donor haematopoietic cells from the recipient 
demonstrates that chimerism is responSible for indUCing toleranceJ<l. 
This fundamental mechanistic difference is also evident in the 
behaviour of subsequent allografts from the same donor after re-
moval of the original transplant. In the case of long-term graft ac-
ceptance induced by immunosuppressive agents, removal of the 
allograft leads to loss of the tolerant sta te over a period of weeks to 
months following explantl'-D Thus, although a second graft is 
usually accepted if transplanted immediately into such recipients, it 
is rejected if the animal is allowed to remain without a graftl2.33 By 
contrast, when tolerance is induced by establishment of mixed 
chimerism, that tolerance is stable after graft remo val. A second allo-
graft from the same donor strain will be accepted without immuno-
generally used, since 100% chimerism is desired to ensure elimi- . suppression at any time thereafter, for the life of the recipient25 
nation of leukaemia cells. By contrast, when chimerism is being used 
to induce transplantation tolerance, complete chimerism is neither 
necessary nor desirable. Instead, it is preferable to achieve a low but 
perSistent level of donor lymphohaematopoietic chimerism, so that 
host-type immune-cell populations are available to provide im-
munocompetence peripherally, while donor-derived cells (probably 
dendritic cells) provide a persistent source of antigen in the thymus, 
capable of effecting negative selection2'. A non-myeloablative pre-
parative regimen, using sublethal irradiation and anti-T-cell mono-
clonal antibodies, has been demonstrated to achieve long-
lasting mix.ed lymphohaematopoietic chimerism without the 
requirement for immunosuppressive therapy beyond the immedi-
ate post-transplant period 25.2 .. Data from these studies showed that 
T-cell depletion and partial ablation of the recipient's immune sys-
tem before bone marrow infusion were required to achieve the per-
sistent level of chimerism necessary to induce tolerance. 
This is not to say that detection of chimerism is not important in 
both cases. Indeed, regardless of the mechanism responsible for the 
establishment of mixed chimerism, its detection might serve as a 
marker for graft acceptance, and thus might be useful diagnostic-
ally. Indeed, cells from the donor which escape to other sites might 
playa role in diminishing the immune response to the transplant22 
However, since detectable microchimerism after organ transplan-
tation is not a consistent finding in patients with short- or long-term 
stable graft function'';, and microchimerism has been shown to per-
sist in patients during graft rejection 23, it might only be useful as a 
marker in conjunction with other parameters3 The detection or lack 
of detection of donor microchimerism after solid-organ transplan-
tation alone may be misleading. 
Clinical implications 
Starzl and colleagues ha ve proposed a paradigm in which the states 
of immunologic tolerance achieved either by bone marrow trans-
Differences between the forms of chimerism detected plantation or by organ transplantation are linked by a common de-
in these situations pendence on the presence of haematopoietic chimerism"" The de-
There is a fundamental difference between the microchimerism de- scription of this paradigm is important both because it provides a 
tected following allogeneic organ transplantation using standard theoretical construct for understanding the complex interactions 
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between host and graft that occur following any transplant, and 
because it suggests experimental manipulations which increase the 
likelihood of tolerance induction and which are therefore worthy of 
further tes ting. However, g iven the likely differences in mechanism 
by which chimerism is achieved in these two d istinct situations, it 
would be prema ture and potentially dangerous to d iscon tinue im-
mu nosuppression in transplant patients solely on the basis 01 the 
detection of peripheral microchimerism. Im munosu ppression gen-
erally diminishes T-cell responses by suppressing the activity of 
T cells capable of recognizing the transplanted tissue rather than by 
eliminating them. Therefore, when immunosuppression is stopped, 
T-cell reactivity to the transplant can be expected to return, unless 
some additional mechanism to delete o r inhibit the acti vity of 
donor-reactive T ce lls is acquired in the interim. 
Such mechanisms may exist and should be explored. For ex-
ample, it might be possible to induce specific anergy among residual 
T cells during the period 01 immunosuppression)4. Alterna tively, if 
cells from the transpla nt migrate to sites capable of achieving nega-
tive selection 01 new T cells, e.g. the thymus, and if sufficien t time 
passes during the period of immunosuppression lor existing T cells 
to be replaced , then a deJetional tolerance could result. However, 
some T cells are known to be extremely long-lived)', thus the period 
necessary for such a resu lt to be achieved could be long and variable. 
Clearly, additional laboratory studies directed towards elucidating 
the mechanisms by which the unresponsive sta te is maintained are 
essential before it will be safe to discon tinue immunosuppression in 
clinical transplantation. 
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Hot tips? 
The launch of Immunology Today Online has created an 
eXciting opportunity for rapid communication of brief 
news items. People and places, science research and 
science politics, all generate information of immediate in-
terest to the immunological community. If you think there 
is something we should know, why not tell us? The 
Immunology Today office can accept fax and e-mail at the 
following numbers: 
Fax +44 1223 464430 
e-mail IT@elsevier.co.uk 
If you let us know, we'll spread the news. 
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Response to Starzl 
et 01. 
with conventional immunosuppression is 
the cause of graft acceptance or the result of 
effective immunosuppression. In order to 
do so they will have to explain why, in the 
case of long-term graft acceptance induced 
Starzl ilnd colleagues hilve provided a COI11- by immunosuppressive drugs, removal of 
prehensive review of the ilrguments that they the allograft leads to the loss of the tolerant 
hilve previously raised in favour of their state, whereas tolerance induced by the es-
'two-way parildigm' of tolerance. However, tablishment of mixed chimerism via bone 
they fail to shed new light on the central marrow transplantation persists for the life-
question of whether the chimerism ob- time of the recipient, regardless of whether 
served following a transplant performed or not the allograft is removed. 
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Response to 
Wood and Sachs 
ance ilre not the same. There is no purpose tors, soluble MHC class I antigens Or as yet 
When the mathematician, Andrew Wiles, 
faced skeptics after proving Fermat's last 
theorem', he said in effect that either he had 
solved the problem or gone mad. A radical 
departure from an ossified dogma provokes 
such thoughts. 
A new idea must be understood to be 
judged . The madness of equating chimerism 
with drug-free tolerance or of using the pre-
in restilting the evidence that the mecha- unidentified molecules (reviewed in Ref. 3). 
nisms are the same, beyond emphasizing It would be unjust not to pOint OLit how 
ou r agreement with Wood and Sachs that dependent the evolution of the two-way 
recipient cytoreduction enhances the ease 
and extent of donor leukocyte engraftment 
in proportion to its severity. 
However, the penalty is proportionate 
weakening of the biologic safety device, 
both against GVHD and rejection. that is 
provided by the nullification mechanism 
of dual cell populations. With each further 
increment in cytoreduction, successful 
transplantation depends more on tissue 
paradigm has been on the past and contin-
uing research of Wood, Sachs and many 
others. To comprehend how the disorien-
tation about transplantation tolerance oc-
curred, it is important to read classical con-
tributions to the literature of mixed 
chimerism4-9 (see Fig. 3, p . 580). The his-
torical observations can be fully under-
stood only in the context of the two-way 
paradigm. 
sence ilnd level of chimerism to guide drug matching. Consequently, the progressive 
weaning is not part of, or derivative from, 
the two-way paradigm. While agreeing un-
reservedly with Wood and Sachs' caution 
not to reckless ly stop immunosuppression, 
we point out that their advice will apply 
equally to clinical use of the mixed chim-
erism models that they describe (see pp. 
584-587). Alread y, this advice is il dominant 
theme in all management protocols of con-
ventional bone marrow transplantation. 
In the liltter context in which the two-
way system is distorted by cytoablation, 
human recipients of major histocompatibil-
ity complex (MHO-matched bone marrow 
routinely require many months of immuno-
suppression to avoid gra ft rejection and the 
converse problem of graft-versus-host dis-
ease (GVHD). Even with an HLA incompat-
ibility of only one allele, the patient is com-
mitted to years of drug therapy to avoid 
these complications. 
Suggestions contrary to the two-way 
paradigm have been attributed to us by in-
accurate citations (summarized in Ref. 2), 
not limited to the reports of wea ning com-
plications used by Wood and Sachs to sup-
port their contention that the mechanisms 
of organ- and bone-marrow-induced toler-
restriction of the acceptable donor pool will 
be a particularly grave handicap if this 
strategy is applied to xenotransplantation. 
We have concluded that failure to find 
microchimerism after successful human or-
gan transplantation, or in clinically relevant 
surrogate animal models, implies an incom-
plete search. In our clinical studies in which 
sampling was from multiple sites, the yield 
from individual locations was comparable 
with yields reported by others. However, 
when the results were pooled from the dif-
ferent sites in indiv idual patients, all 30 
tested patients had microchimerism. In rat 
experiments where tissues could be re-
trieved without limit, the association of 
chimerism with a voidance of chronic 
rejection has been absolute in Our hands. 
The conceptual flaw of using classical 
'parking models' to study tolerance mecha-
nisms was discussed previously in this 
issue (pp. 577-584). We have left open the 
possibility that the organ parenchymal cells 
facilitate chimerism by cont ributing to a fa-
vorable microenvironment, most likely by 
regional secretion of granulocyte-macro-
phage colony-stimulating factor (GM-CSF), 
G-CSF, other growth and anti-growth fac-
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